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Protein deliveryHere we report a novel strategy for the induction of CD8+ T cell adaptive immune response against viral and
tumor antigens. This approach relies on high levels of incorporation in HIV-1 VLPs of a mutant of HIV-1 Nef
(Nefmut) which can act as anchoring element for foreign proteins. By in vitro assay, we found that VLP-
associated Nefmut is efﬁciently cross-presented by antigen presenting cells. Inoculation in mice of VLPs
incorporating the HPV-16 E7 protein fused to Nefmut led to an anti-E7 CD8+ T cell response much stronger
than that elicited by E7 recombinant protein inoculated with incomplete Freund's adjuvant and correlating
with well-detectable anti-E7 CTL activity. Most relevantly, mice immunized with Nefmut-E7 VLPs developed
a protective immune response against tumors induced by E7 expressing tumor cells. These results make
Nefmut VLPs a promising candidate for new vaccine strategies focused on the induction of CD8+ T cell
immunity.
© 2009 Elsevier Inc. All rights reserved.Introduction
Virus spread in infected host can be prevented and/or counter-
acted by virus-speciﬁc antibodies through the neutralization process
(Klasse and Sattentau, 2002; Reading and Dimmock, 2007). However,
in many instances, particularly in established infection, this cannot be
sufﬁcient, and the control and clearance of viral infection require the
contribution of alternative immune mechanisms. Among these,
speciﬁc CD8+ cytotoxic T lymphocytes (CTLs) are crucial for virus
clearance in view of their ability to recognize and kill virus-infected
cells. The protective function of CTLs can also be relevant in virus-
induced tumors, as well as in virus-independent cancers, due to the
recognition of tumor-associated antigens.
Several immunogens have proven suitable for induction of speciﬁc
CTLs, including attenuated viruses (Wang et al., 2006), recombinant
viral vectors (He et al., 2007; Yang et al., 2007; Liniger et al., 2007),).
ll rights reserved.and naked DNA (Anderson and Schneider, 2007; Liu and Ulmer,
2005). However, both safety concerns and scarce efﬁcacy have limited
their approval for humans. Virus-like particles (VLPs) represent a
promising tool for overcoming these limitations. They are self
assembling, non-replicating, non-pathogenic, genomeless particles
(Grgacic and Anderson, 2006). VLPs can be engineered to incorporate
foreign antigens (chimeric VLPs) as in the case of human immuno-
deﬁciency virus type 1 (HIV-1) Pr55gag -derived VLPs, whose
immunogenicity can be broadened by the inclusion of chimeric Gag
molecules (Buonaguro et al., 2006; Luo et al., 2007; Paliard et al., 2000;
Wagner et al., 1994; Young and Ross, 2006). However, their
assembling efﬁciency is affected by both domain of insertion
(Kattenbeck et al., 1997) and length of exogenous sequences (Muller
et al., 2004).
HIV-1 Nef is a 27-kDa myristoylated protein incorporating in
virions at low levels, i.e., about 10 molecules for viral particle
(Bukovsky et al., 1997; Pandori et al., 1996). We previously
characterized a Nef mutant (Nef7) exhibiting unique efﬁciency of
incorporation (about 100-fold higher than the wild-type protein)
(Peretti et al., 2005). Moreover, this mutant lacks several anti-cellular
effects typically induced by wild-type Nef, including CD4 down-
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et al., 2001), and MHC Class I down-regulation (Green et al., 2009).
Most importantly, Nef7 has been shown to act as carrier of
heterologous proteins fused to its C-terminus (Green et al., 2009;
Peretti et al., 2006). As we recently described, HIV-1 wild-type Nef
carrying the G3C mutation (creating a palmitoylation site at the N-
terminus) shows an incorporation efﬁciency similar to Nef7 (Muratori
et al., 2006). Here, these Nef mutants were combined in a single Nef
molecule (here referred to as Nefmut) and fused with the human
papilloma virus (HPV)-E7 protein to recover VLPs incorporating high
amounts of the Nefmut/E7 fusion product.
The “high-risk” HPV (HR-HPV) genotypes are recognized as
etiologic agents of invasive cervical cancer, its precursor lesions, and
other kinds of anogenital tumor. The two early viral proteins E6 and
E7 are the most frequently targeted antigens for immunotherapeutic
approaches against HPV-related cancer. These proteins are constitu-
tively expressed in HPV-associated lesions, and their expression is
required for maintenance of the cell transformed state. They
contribute to events leading to cellular malignant conversion by
interacting with cellular partners. The E7 ultimate effect is up-
regulation of genes required for G1/S transition of cell cycle and
cellular DNA synthesis, whereas E6 targets cellular proteins involved
in apoptosis control, growth arrest, terminal cell differentiation, and
antiviral defense (Fehrmann and Laimins, 2003; Munger et al., 2004).
Several lines of evidence suggest that CD8+ T-cell-mediated immune
response is important in controlling HPV infection and, by conse-
quence, virus-associated neoplasia. Accordingly, immune suppression
and/or poor anti-HPV E7 CTL response has been associated with viral
persistence and disease progression (Bourgault et al., 2004).
Several vaccine platforms targeting E7 and/or E6 have been
developed over the last decade (Brinkman et al., 2007) including
peptide/protein-based therapies, viral vector-based therapies, and
dendritic cell-based therapies (Bellone et al., 2007). ProphylacticFig. 1. Summary of the method for the production of Nefmut-based VLPs through the tranvaccines preventing infection by the HR-HPV type-16 and type-18 are
now available. However, these vaccines have no effect against pre-
existing HPV infection and HPV-associated lesions. Furthermore, due
to the long latency from infection to cancer, their eventual beneﬁts
will be visible within decades. Thus, developing new therapeutic
strategies to cure the already infected individuals remains a priority.
Pseudotyping VLPs with the glycoprotein of vesicular stomatitis
virus (VSV-G) is expected to improve their efﬁciency of delivery into
antigen presenting cells (APCs) as well as to favor CD8+ T cell immune
response through cross-presentation and cross-priming mechanisms.
In fact, VSV-G allows VLPs to enter APCs through endocytosis, thereby
promoting the fusion between VLP envelope and endosome mem-
branes. This guarantees efﬁcient delivery of VLP contents into
cytoplasm, thus facilitating their interaction with proteasome, protein
degradation, and association with Class I MHC molecules (Marsac
et al., 2002).
Here, we report that (VSV-G) VLPs incorporating Nefmut fused
with HPV type-16 E7 induced an anti-E7 CTL response correlating
with protection from HPV-related tumor. This result represents the
proof of principle that (VSV-G) Nefmut-based VLPs can indeed
represent an useful tool for the induction of CD8+ T cell adaptive
immune response against heterologous proteins for vaccination
purposes.
Results
Construction of (VSV-G) HIV-1 based Nefmut VLPs
Both Nef7 and G3C Nef mutants incorporate at high levels in HIV-1-
derived VLPs and act efﬁciently as carrier molecules (Peretti et al.,
2005; Muratori et al., 2006). In Fig. 1, the design of the Nefmut-based
VLP system is summarized. In detail, the G3C mutant of Nef7 (here
referred to as Nefmut) fused with a foreign antigen was packaged intosfection of vectors into 293 GPR HIV-1 packaging cells. Cell and VLP are not in scale.
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expression vectors into 293 GPR packaging cells which express HIV-
1 Gag-Pol in an inducible manner. After induction, the released VLPs
were harvested and concentrated/puriﬁed by ultracentrifugation on
sucrose cushion. VLPs were recovered as the pellet fraction and used
for both molecular characterization and immunogenicity tests.
Cross-presentation of Nef mut in APCs challenged with (VSV-G) Nef mut
HIV-1 VLPs
The cross-presentation in APCs of HIV-1 Gag products in the
absence of viral replication has been already described (Buseyne et al.,
2001). Conversely, nothing has been reported about Nef. We
attempted to ﬁll this gap taking advantage of the high virion
incorporation extents of Nefmut. Cross-presentation of Nefmut deliv-
ered by VLPs was evaluated by an in vitro assay based on the co-
culture of VLP-challenged human B-lymphoblastoid cell lines (B-LCLs)
with MHC Class I-matched, Nef-speciﬁc CD8+ T-cell lines. We ﬁrst
evaluated the efﬁciency of VLP entry into B-LCLs by challenging these
cells with ﬂuorescent (VSV-G) VLPs incorporating Nefmut-GFP fusion
molecules. In particular, 500-ng HIV-1 CAp24 equivalents of these
VLPs were used to challenge 105 B-LCLs which, at different times,
were harvested, incubated with trypsin 15 min at 37 °C, and ﬁxed. As
control, the challenge was performed at 4 °C or using receptor-less
Nefmut-GFP VLPs (null VLPs). FACS analysis (Fig. 2A) indicated the
presence of high levels of ﬂuorescent products into the B-LCLs as early
as 4 h after challenge. Conversely, no cell-associated ﬂuorescence was
detected when the cells were incubated at 4 °C or using Null VLPs.
These results demonstrated that (VSV-G) Nefmut-based VLPs can be
efﬁciently internalized by human B-LCLs.
To assess whether VLP-associated Nefmut undergoes cross-
presentation, we evaluated the cell activation in terms of IFN-γ
production by Nef-speciﬁc CD8+ T cells co-cultured with MHC Class I-
matched B-LCLs previously challenged with VLPs. In particular, HLA-
B7 B-LCLs were challenged with either 500-ng HIV-1 CAp24
equivalents of (VSV-G) Nefmut VLPs/105 cells or the same amounts
of VLPs not incorporating Nef (Void VLPs). After 3 h of absorption,
cells were extensively washed and put in co-culture at 1:2 ratio with a
CD8+ T-cell line speciﬁc for the TPGPGVRYPL HLA-B7 restricted Nef
epitope. As positive control, co-cultures including B-LCLs pre-treated
for 16 hwith the B7-restricted Nef peptide were also carried out. After
overnight incubation, supernatants were harvested for the determi-
nation of IFN-γ contents, and the co-cultures were re-seeded in fresh
medium in the presence of brefeldin A. Five hours later, the co-
cultures were analyzed by FACS for the expression of both CD8 and
IFN-γ. The results obtained by both FACS and ELISA assays (Fig. 2B)
consistently documented the production of IFN-γ in the indicator
CD8+ lymphocytes. Conversely, no IFN-γ production was detectable
in co-cultures with B-LCLs challenged with void VLPs. Of note,
similar results were obtained using a CD8+ T-cell line speciﬁc for the
RRQDILDLWIY HLA-Cw7 restricted Nef epitope (not shown).
We concluded that (VSV-G) HIV-1 Nefmut-based VLPs efﬁciently
enter B-LCLs, and that VLP-associated Nefmut molecules undergo
effective antigen cross-presentation. These results appeared parti-
cularly signiﬁcant also considering the moderate to low cross-
presentation activity previously described in human B-LCLs (Munz
et al., 2000; Sallusto and Lanzavecchia, 1994).
Recovery of HPV-E7 incorporating VLPs
The interest in the Nefmut-based VLP system as novel vaccine
platform relies on its ability to elicit effective immune response against
the foreign moiety fused with Nefmut. We selected HPV type-16 E7
protein as heterologous antigen in view of its potent immunogenicity
and its involvement in the induction and maintenance of HPV-related
cell transformation. Moreover, a well-characterized animal model forHPV-related tumors is available for evaluating the effectiveness of
anti-HPV vaccination strategies.
We produced VLPs incorporating the products of fusion between
Nefmut and either wild-type or E7GGG isoforms, the latter being a non-
oncogenic mutant unable to bind the cellular pRb protein due to three
amino acid substitutions within the pRb binding site, i.e., D21G, C24G,
and E26G (Smahel et al., 2001). The intrinsic stability of the fusion
products was assessed by anti-Nef Western blot analysis of lysates
from 293T cells transfected with the respective vectors (Fig. 3A). Both
full-length Nefmut-E7 and Nefmut-E7GGG fusion products were
detected in amounts comparable to Nefmut alone, which was
suggestive of intrinsic stability of the fusion products comprising E7.
This is of relevance since E7 has been described to be a quite unstable
protein (Selvey et al., 1994). On the other hand, both anti-Nef and
anti-E7 Western blot analyses of VLPs puriﬁed from supernatants of
packaging cells showed that the fusion products were efﬁciently
incorporated in their full-length forms and at similar extents (Fig. 3B).
To more accurately evaluate the VLP incorporation extents of
Nefmut-E7 fusion products, semi-quantitative Western blot assays on
puriﬁed VLPs were also performed (Fig. 3C). In detail, the signals
produced by scaled quantities of recombinant (r)Nef protein and of
Nefmut-E7 VLPs (measured in nanograms of VLP-associated HIV-1
CAp24) were evaluated by densitometric analysis (not shown). We
observed that the signal from 62.5-ng CAp24 of Nefmut-E7 VLPs had an
intensity similar to that from 12.5 ng of rNef, indicating that Nefmut-
E7 associated with VLPs at a mass ratio of approximately 1:5 as
compared with CAp24. Similar results were obtained for the VLP
incorporation of Nefmut-E7GGG (data not shown).
Hence, both HPV-E7 and E7GGG are incorporated at high levels in
(VSV-G) Nefmut-based VLPs, which are therefore suitable candidates
for anti-HPV vaccination studies.
Nefmut-E7 molecules delivered by VLPs do not affect Class I MHC
expression
The expression of HIV-1 Nef in infected cells correlates with
induction of relevant mechanisms of immune evasion mainly
mediated by down-regulation of MHC Class I (Schwartz et al., 1996;
Wonderlich et al., 2008), and similar effects have been demonstrated
for HPV-E7 (Bottley et al., 2008). Thus, before analyzing the
immunogenicity of Nefmut-E7 VLP, the impact of the delivery of
Nefmut-E7 molecules on MHC Class I expression in professional APCs,
e.g., human immature monocyte-derived dendritic cells (iDCs), was
accurately evaluated. In this perspective, iDCs were preventively
assayed for their ability to internalize ﬂuorescent (VSV-G) VLPs
(Fig. 4A). We observed VLP uptake in a signiﬁcant part of the cell
population 2 h after challenge, and in the most part of iDCs after 4 h.
Identical results were achieved by challenging mature human DCs as
well as primary murine iDCs (data not shown).
We analyzed the expression of MHC Class I on the surface of iDCs
16 h after challenge with 500 ng HIV-1 CAp24 equivalents/105 cells of
Void, Nefmut, or Nefmut -E7 (VSV-G) VLPs. As shown in Fig. 4B, no
modulation of MHC Class I expression was detectable in any
challenged iDC population, and similar results were observed 4 and
8 h after challenge (data not shown). Experiments of Nefmut-E7GGG
VLP uptake in iDCs generated analogous results (not shown).
These data indicate that the VLP-mediated delivery of Nefmut alone
or in combination with E7 does not induce detectable effects on the
surface MHC Class I expression of iDCs, thus allowing unbiased
analyses of the immunogenicity of Nefmut-based VLPs.
In vivo induction of anti-E7 T cell immune response by (VSV-G)
Nef mut-E7 VLPs
Next, we sought to evaluate the efﬁciency of Nefmut-based VLPs in
inducing speciﬁc CD8+ T cell adaptive immune response against HPV
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consisting in three subcutaneous inoculations in C57 Black/6 mice of
10 μg CAp24 equivalents of (VSV-G) VLPs at 2-week intervals. Mice
were inoculated with VLPs incorporating Nefmut alone or fused with
HPV E7 or E7GGG or with void VLPs. After two additional weeks, mice
were sacriﬁced and cultures of explanted splenocytes were carried
out for 4 days in the presence of E7 or control peptides. Finally, the
presence of activated E7-speciﬁc CD8+ lymphocytes was tested by
IFN-γ ELISpot assay. As shown in Fig. 5A, we reproducibly detected a
number of IFN-γ producing cells much higher in splenocyte cultures
from mice inoculated with either Nefmut-E7 or Nefmut-E7GGGVLPs
than in splenocytes from control conditions. Concerning the humoral
immune response, weak anti-E7 and anti-Nef antibody responses
were observed in sera from inoculated mice (not shown), in the
presence, however, of well-detectable anti-Gag antibodies with titers
ranging from 1:800 to 1:1600, with no signiﬁcant variations among
the different groups.
Next, we compared the antigen-speciﬁc CD8+ T cell immune
responses induced by E7-based VLPs with that elicited by recombi-
nant E7 protein. To this end, mice received three injections with 2-
week intervals of 10 μg HIV-1 CAp24 equivalents of (VSV-G) VLPs
incorporating either Nefmut alone or the Nefmut-E7 fusion protein.
Meanwhile, another group of mice received three doses of 10 μg of rE7
protein emulsiﬁed in incomplete Freund's adjuvant. Two weeks after
the last inoculation, mice were sacriﬁced, and splenocytes isolated
and cultured in the presence of E7 or control peptides. After 4 days of
incubation, cell activation was evaluated by IFN-γ ELISpot assay. As
reported in Fig. 5B, we detected signiﬁcantly higher E7-speciﬁc
response in splenocytes from mice inoculated with Nefmut-E7 VLPs
with respect to the response detectable in splenocytes from rE7
inoculated mice. Of note, to properly compare the responses elicited
by VLP-delivered E7 and rE7, it should be considered that miceFig. 2. Nefmut delivered by VLPs is cross-presented by B-LCLs. (A) Kinetic of internalization
challenged at 4 °C with (VSV-G) Nefmut-GFP VLPs, maintained for 4 h at the same temperatur
GFP VLPs or with the receptor-less counterpart (Null), and FACS analyzed after different tim
challenge. Results are representative of three independent experiments. (B, C) HLA-B7 B-LCL
in co-culture with a CD8+ T-cell line speciﬁc for an HLA-B7 restricted Nef epitope. As contro
later, cells were FACS analyzed for the expression of both CD8 and IFN-γ upon treatment for
IFN-γ intracellular staining on the basis of the forward scatter/anti-CD8 proﬁle are shown. P
both CD8 and intracellular IFN-γ expression on the same cell populations are shown, and the
supernatants as measured by ELISA. Mock: supernatants fromHLA-B7-restricted Nef-speciﬁc
carried out with triplicate conditions (B) or are reported as the mean values (C) from the sreceived equivalent amounts of HIV-1 Gag and rE7 proteins, and that,
as here reported, Nefmut-E7 molecules associate with VLPs about ﬁve
times less efﬁciently than HIV-1 Gag products. In addition, E7
represents only about one-third of the whole Nefmut-E7 fusion
molecule. Thus, the amount of rE7 administered to mice was about
15-fold higher than that of E7 delivered by VLPs. Notwithstanding,
VLP-associated E7 generated a cell immune response about three
times stronger than rE7.
In conclusion, these data strongly suggest that the incorporation
into (VSV-G) HIV-1-based VLPs of a foreign antigen as part of a
Nefmut-based fusion product is an effective tool to elicit a potent CD8+
T-cell-mediated immune response.
Detection of anti-E7 CTL activity in cultures of splenocytes from mice
inoculated with (VSV-G) Nefmut-E7 VLPs
Next, we asked whether the anti-E7 cell immune response
induced by the Nefmut-based VLPs associated with a detectable
cytotoxic activity. To this end, splenocytes pooled from mice
immunized with (VSV-G) VLPs incorporating either Nefmut or
Nefmut-E7 were cultivated in the presence of E7 peptides for 4 days.
Afterwards, the CD8+ cell fraction was puriﬁed and co-cultivated for
6 h at scalar cell ratios from 40:1 to 5:1 with murine EL-4 cells
previously loaded with either E7-speciﬁc or control peptides. The
cytotoxic activity was ﬁnally evaluated by FACS analysis as the
percentage of cell mortality in EL-4 target cells. We noticed that EL-4
cells were killed much more efﬁciently by the CD8+ cells recovered
from mice immunized with Nefmut-E7 VLPs than by those from
control mice (Fig. 6). Considering that EL-4 cells are resistant to the
cytotoxic activity of CD8+ NK cells (Fostel et al., 2006), our results
strongly suggest that the inoculation of Nefmut-E7 VLPs indeed
induced anti-E7-speciﬁc CTLs.of (VSV-G) Nefmut-GFP VLPs in human B-LCLs. On the left: B-LCLs were untreated or
e, and ﬁnally FACS analyzed. On the right: B-LCLs were challenged with (VSV-G) Nefmut-
es of incubation at 37 °C. Cells incubated with Null VLPs were analyzed only 4 h after
s were challenged with either (VSV-G) Nefmut VLPs or the void counterpart and then put
l, B-LCLs were also treated with 5 μg/ml of the B7-restricted Nef peptide. Sixteen hours
5 h with brefeldin A (B). In the top row, the cell populations selected for antigen-speciﬁc
ercentages of IFN-γ-positive cells are reported. FSC: forward scatter. In the bottom row,
percentages of IFN-γ/CD8-positive cells reported. (C) IFN-γ contents in the co-culture
CD8+ cells cultivated alone. Results are representative of two independent experiments
ame two experiments.
Fig. 2 (continued).
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In view of the good cytotoxic activity exerted by splenocytes from
mice immunized with Nefmut-E7 VLPs, we were encouraged to
evaluate whether this vaccination approach could induce a protective
effect against experimental tumors induced by the inoculation of TC-1
cells, i.e., a C57 Black/6 mice-derived cell line expressing HPV-E7 (Lin
et al., 1996). To this end, mice (nine per group) received three
injections of VLP resuspension medium (control mice) or of 10-μg
HIV-1 CAp24 equivalents of either Nefmut or Nefmut-E7 VLPs at 2-
week intervals. After two additional weeks, mice were inoculated
subcutaneously with 5×104 TC-1 tumor cells. As depicted in Fig. 7, the
majority of mice inoculated with the Nefmut-E7 VLPs rejected the TC-1
tumor cells, whereas control mice or mice immunized with Nefmut
VLPs developed visible and progressively growing tumors. Tumor
growth appeared slightly delayed in mice inoculated with VLPs
incorporating Nefmut alone as compared with naïve mice. Thisobservation suggests a low-grade, innate immune activation induced
by the inoculation of (VSV-G) Nefmut VLPs.
Taken together, these data are suggestive of the potential
usefulness of Nefmut-based VLPs as anti-tumor vaccines. In addition,
these results are consistent with the assumption that a strong anti-E7
CTL response contributes to the eradication of HPV-related tumors.
Discussion
It was previously reported that HIV-1 Gag products can be cross-
presented to induce efﬁcient CD8+ T-cell-adaptive immune response
(Buseyne et al., 2001; Marsac et al., 2002; Moris et al., 2004).
Extending this ﬁnding to products incorporated into HIV-1 virions
allowed to conceive the Nefmut-based VLP system as a platform for the
preferential induction of CD8+ T cell immune response.
We assayed the immunogenicity of the foreign moiety delivered
by the Nefmut-based VLPs in the context of the HPV model. HPV E7 is
Fig. 3. Molecular characterization of (VSV-G) VLPs incorporating Nefmut-E7 fusion products. (A) Anti-Nef Western blot analysis of 30 μg of proteins from lysates of 293T cells
transfected with vectors expressing the indicated products. (B) Western blot analysis of 500 ng of HIV-1 CAp24 equivalents of (VSV-G) VLPs incorporating the indicated fusion
products and carried out with either anti-Nef, anti-E7, and anti-VSV-G Abs. (C) Quantitation of Nefmut-E7 virion incorporation. Two-fold serial dilutions of (VSV-G) Nefmut-E7 VLPs
were analyzed by anti-Nef Western blot for the presence of Nefmut-E7 as compared with serial dilutions of rNef. The amounts, in nanograms, of both rNef and VLP-associated HIV-1
CAp24 are indicated on the top. In all panels, arrows indicate the speciﬁc signals, and molecular markers are given in kilodaltons (kDa). Results are representative of four (A), eight
(B), and three (C) independent experiments.
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in the malignant transformation occurring upon persistent HPV cell
infection and, together with E6, is stably expressed in transformed
keratinocytes of HPV infected patients (Munger et al., 2004). The
induction of E7-speciﬁc CD8+ T cell response in mice inoculated with
either Nefmut-E7 or -E7GGG VLPs is consistent with the idea that
products fused with Nefmut undergo efﬁcient cross-presentation
similarly to that observed for Nefmut in the in vitro antigen cross-
presentation assay. We have no obvious explanation for the lower
anti-E7 cell immune response induced by VLP-associated E7GGG
compared with wild-type E7. Clearly, it did not depend on differences
in VLP incorporation levels.
Nefmut-E7 VLPs elicited a very poor antibody response against both
Nef and E7 in immunized mice, suggesting that the VLP-associated
fusion product preferentially enter the MHC Class I presentation
pathway. On the other hand, the induction of sustained levels of anti
HIV-1 Gag antibodies was likely due to free Gag products usually co-
purifying with HIV-1 particles.
The anti-E7 cell immune response elicited by VLP-associated E7
appeared to be signiﬁcantly stronger than that generated by
recombinant E7. This result is of relevance since it represents the
signiﬁcant added value of Nefmut-based VLP system over recombinantproteins in terms of induction of CD8+ T cell immune response. Of
course, it will be important to extend this ﬁnding to additional viral
and tumor antigens.
In this study, we have tested the capacity of E7 delivered by Nefmut-
based VLP system to counteract an HPV-related tumor in a preventive
setting. Our results strongly suggest a correlation between the
development of E7-speciﬁc CTLs induced by the inoculation of Nefmut-
E7 VLPs and the growth inhibition of E7 expressing tumor cells. Similar
results have been previously obtained in anti-E7 therapeutic experi-
mental vaccinations. In particular, the eradication of established HPV-
expressing tumors in animalswas obtainedby administration of vaccine
composed of a liposome-encapsulated E7-speciﬁc CTL-T helper fusion
peptide (Daftarian et al., 2006) or of chimeric HPV-like particles
expressing L1-E7 fusion protein (Schafer et al., 1999). In both cases,
vaccines induced E7-speciﬁc CTL response in mice, which thus is
regarded as essential for a therapeutic approach focused on the
eradication of established HPV E7-induced tumors in animal models.
The cell-mediated immune response we obtained in animal vaccination
with Nefmut-E7 VLPs appeared efﬁcient in counteracting the tumor cell
growth. On this subject, it is important to point out that, even if in our
systemmicewere challengedwith tumor cells after VLP inoculation, this
immunization strategy has some analogy to a true therapeutic approach
Fig. 4. Expression of cell membraneMHC Class I in iDCs is not affected by the challenge with (VSV-G) Nefmut-based VLPs. (A) Kinetic of internalization of (VSV-G) Nefmut-GFP VLPs in
iDCs. FACS analysis of iDCs at different times after challenge with (VSV-G) Nefmut-GFP VLPs (top row) or 4 h after challenge with the receptor-less counterpart (Null VLPs) (bottom
row). As additional control, (VSV-G) Nefmut-GFP VLP-treated iDCs were also maintained for 4 h at 4 °C. SSC: side scatter. (B) MHC Class I expression in VLP-challenged iDCs. Human
iDCs were mock infected or challenged with 500 ng HIV-1 CAp24 equivalents/105 cells of (VSV-G) void, Nefmut, or Nefmut-E7 VLPs, or with an equivalent volume of medium (Mock),
and 16 h later FACS analyzed for the expression of MHC Class I. Control of VLP internalization efﬁciency was carried out in parallel conditions using the same amounts of (VSV-G)
Nefmut-GFP VLPs (not shown), and only experiments showing ≥80% of VLP cell internalization were considered. M1 identiﬁes the range of positivity as determined by labeling the
cells with control IgG isotype. The percentages of positive cells are indicated in plots of both panels. Results are representative of three independent experiments.
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(Bourgault et al., 2004; Hung et al., 2007).
Our data open the way towards the exploitation of CD8+ T cell
immune response against additional viral and tumor antigens
delivered by Nefmut-based VLPs. The most signiﬁcant advantages of
the Nefmut VLP platform over other viral vector-based vaccine
strategies can be summarized as follows: (i) VLPs are immunogenic
in the absence of genetic material transfer; (ii) in particular, Nefmut-
based VLPs include only four viral products besides Nefmut-based
fusion protein, that, of major importance, is incorporated at rather
high levels and can accommodate quite large proteins (i.e., up to 630
amino acids) without signiﬁcant impairment of both VLP assembling
and cell entry (unpublished results). Conversely, alternative chimeric
VLP systems based on assembling of few antigen types (i.e., HBV core
VLPs) can accommodate only small epitopes, thus rendering thedevelopment of universal vaccines quite complicate; (iii) similarly to
retro- and lentiviral vectors, Nefmut-based VLPs can be easily
pseudotyped with different receptors. Differently pseudotyped VLPs
could be of utility to circumvent the antibody-mediated VLP
neutralization occurring after multiple immunizations; and (iv) as
an alternative to HIV-1 VLPs, the Nefmut-based-VLP system can be
translated into the Moloney Leukemia Virus system without loss of
efﬁciency (Peretti et al., 2005).
Finally, it is also conceivable that co-inoculation of VLPs carrying
different immune determinants from the same pathogen (e.g.,
different antigens from the same virus) would generate a pool of
CTLs that could synergize in an immune response difﬁcult to obtain
with current vaccine designs. For all these reasons, the Nefmut-based
VLP system would be considered a very promising tool for the
development of still unexplored vaccine strategies.
Fig. 5. Cellular immune response in mice inoculated with (VSV-G) Nefmut-based VLPs
or recombinant E7. (A) C57 Black/6 mice (at least ﬁve per group) were inoculated with
empty VLPs (Void) or with VLPs incorporating the indicated Nefmut-based products. As
additional control, mice were also inoculated with equivalent volumes of medium
(Naive). Splenocytes recovered frommice of each groupwere pooled, and incubated for
4 days with 5 μg/ml of either control (open bars), or E7 peptides (closed bars).
Afterwards, the cell activation extents were evaluated by IFN-γ ELISpot assay carried
out in triplicate with 105 cells/well. Shown are the mean+SD number of IFN-γ spot-
forming cells (SFU)/105 cells from four independent experiments. (B) Comparative
analysis of the anti-E7 cell immune response in (VSV-G) Nefmut-E7 VLP versus rE7
inoculated mice. C57 Black/6 mice (three per group) were inoculated as described with
empty VLPs (Void), VLPs incorporating either Nefmut or the Nefmut-E7 fusion product,
or with rE7 protein and adjuvant. As additional control, mice were also inoculated with
equivalent volumes ofmedium (Naive). Splenocytes recovered frommice of each group
were pooled, and the cell activation assay was completed as here above described.
Shown are the mean+SD number of IFN-γ SFU/105 cells from three independent
experiments.
Fig. 6. CTL assay carried out with CD8+ cells from VLP inoculated mice. Splenocytes
from mice (ﬁve per group) inoculated with either (VSV-G) Nefmut or Nefmut-E7 VLPs
were pooled and cultured for 4 days in the presence of E7 peptides. Thereafter, the CD8+
cell fraction was isolated and then co-cultivated for 6 h at the indicated cell ratios with
EL-4 cells pre-treated with control or E7 peptides for 16 h. Finally, co-cultures were
labeled with FITC-conjugated anti-CD8 mAbs, and the cell mortality in EL-4 cell
population was scored by FACS analysis upon propidium iodide (PI) labeling. Shown are
the mean+SD values calculated from three independent experiments.
Fig. 7. Anti-tumor activity of Nefmut-based VLPs. C57 Black/6 mice (nine per group)
were inoculated three times with (VSV-G) VLPs incorporating the indicated Nefmut-
based products. As control, mice were also inoculated with equivalent volumes of
medium (Naive). Two weeks after the last inoculation, mice were challenged with
5×104 TC-1 cells, and tumor growth was monitored once a week. Results are
representative of two independent experiments.
52 P. Di Bonito et al. / Virology 395 (2009) 45–55Materials and methods
Cell cultures
For the recovery of HLA-B7-restricted Nef-speciﬁc CD8+ T-cell
line, peripheral blood mononuclear cells (PBMCs) from previously
characterized HIV-1-infected individuals (Cosma et al., 2003) were
stained using ﬂuorochrome-linked TPGPGVRYPL/HLA B7 MHC Class I
multimers. The cells were then sorted with a Moﬂo cell sorter
(Cytomation, Fort Collins, CO, USA) and expanded in the presence of
anti-CD3mAb (OKT3; Janssen-CILAG, Neuss, Germany), rIL-2 (Chiron,
Emeryville, CA), rIL-15 (Sigma, Milwaukee, WI), and irradiated B-LCLs
and PBMCs as feeder cells as previously described (Geretti et al.,
1996). Similar procedures were carried out for the generation of HLA-
Cw7 restricted RRQDILDLWIY-speciﬁc CD8+ T-cell line, except that
PBMCs from HIV-1 infected patients were stimulated with the speciﬁc
peptide and antigen-speciﬁc response evaluated by the IFN-γ
Secretion Assay (Miltenyl Biotech, Bergisch Gladbach, Germany)according to the manufactory protocol. Antigen-speciﬁc CD8+ T-cell
lines were regularly monitored for their speciﬁcity by antigen-
dependent intracellular cytokine staining (Kutscher et al., 2008).
Human B-LCLs were generated from peripheral blood mononuclear
cells puriﬁed by standard Ficoll (Biochrom, Berlin, Germany) density
centrifugation according to a previously described method (zum
Buschenfelde et al., 2001) and cultivated in RPMI, 10% decomple-
mented fetal calf serum (FCS).
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inducible packaging cells (Sparacio et al., 2001), and TC-1 cells (Lin
et al., 1996) were grown in DMEM plus 10% FCS. Human primary iDCs
were differentiated from puriﬁedmonocytes upon 5–8 days culture in
RPMI medium supplemented with 20% FCS, 30 ng/ml GM-CSF
(Serotec Ltd, Oxford, UK), and 500 U/ml IL-4 (R&D Systems, Oxford,
UK). DC phenotype was routinely characterized by FACS analysis as
described below. EL-4 cells, a murine thymic lymphoma CD4+ cell line
obtained from C57 Black/6 mice upon treatment with 9,10-dimethyl-
1,2-benzanthracene (Gorer, 1950), were cultivated in RPMI medium
supplemented with 10% of FCS.
VLP production and characterization
The open reading frames coding for GFP and HPV-16 E7 and E7GGG
(i.e., a non-tumorigenic E7 allele mutated in the pRb binding site)
(Smahel et al., 2001) fused at the C-terminus of Nefmut were recovered
by overlapping polymerase chain reaction (PCR)-based protocols and
then inserted in the pcDNA3.1 vector (Invitrogen, Carlsbad, CA). All
constructs were accurately sequenced and selected for the absence of
nucleotide mutations. The 293 GPR cells were used as HIV-1 packaging
cells for VLP production. In these cells, gag-pol genes are expressed
under control of an ecdysone-inducible promoter, so that the lentiviral
particle production requires cell stimulation with the ecdysone
analogue ponasterone A (PonA). VLPs were obtained by co-transfecting
immediate–early CMV promoted vectors expressing the respective
Nefmut-fused products and the VSV-G protein by Lipofectamine 2000
(Invitrogen). Transfected 293 GPR cells were induced 8 h post-
transfection with 5 mM sodium butyrate and 2 μM of PonA. Twenty-
four hours later, supernatants were replaced with fresh medium
containing the inducers. VLP containing supernatants were ﬁnally
harvested 24 and 48 h later, clariﬁed, and concentrated by ultracentri-
fugationon20%sucrose cushion100,000×g, 2 h at4 °C. VLPpreparations
were titrated bymeasuringHIV-1 CAp24 contents by quantitative ELISA
(Innogenetics, Gent, Belgium) and by reverse transcriptase assay.
Western blot analyses of 293T cells transfected with Nefmut-based
expressing vectors were performed by lysing cells in PBS, 1% Triton X-
100 in the presence of anti-proteolytic agents. Cell lysates were then
centrifuged at 6000×g for 10 min at 4 °C and supernatants frozen at
−80 °C. Aliquots of 30 μg of total cell proteins were separated in 10%
SDS–PAGE, thereby undergoing immunoblot analysis. For Western
blot analysis of VLPs, 500-ng HIV-1 CAp24 equivalents of VLPs were
lysed as described for the cells and then separated in 10% SDS–PAGE.
Filters were revealed using the following Ab preparations: sheep anti-
Nef antiserum ARP 444; anti-HPV E7 monoclonal antibody from
Zymed (S. Francisco, CA); and polyclonal anti-VSV-G protein from
Immunology Consultant Laboratories (Newberg, OR). For the semi-
quantitative Western blot analysis, serial amounts of rNef prepara-
tions obtained and quantiﬁed as previously described (Federico et al.,
2001) were included.
VLP endocytosis assay
For APC challenge studies, 500-ng HIV-1 CAp24 equivalents of
VLPs/105 cells were adsorbed on B-LCL by spinoculation at 150×g for
30 min at room temperature (r.t.). In the case of iDC challenge, equal
VLP amounts were adsorbed through 2 h of incubation at 37 °C in 20 μl
of volume. Afterwards, cells were re-fed by adding fresh medium and
incubated at 37 °C. Finally, cells were treated for 15 min with trypsin
at 37 °C, ﬁxed with 2% v/v formaldehyde in PBS, and FACS analyzed.
Cross-presentation assay
HLA-B7 and -Cw7 B-LCLs were challenged by spinoculation with
500-ng HIV-1 CAp24 equivalents of (VSV-G) Nefmut VLPs/104 cells
and, after 3 h of incubation, were extensively washed and co-cultured at 1:2 ratio with Nef-speciﬁc and HLA-B7 or -Cw7 restricted
CD8+ T-cell lines. After overnight incubation, supernatants were
harvested, and co-cultures were seeded in fresh medium in the
presence of 5 μg/ml brefeldin A (BD Pharmingen, San Diego, CA). Five
hours later, co-cultures were FACS analyzed for the expression of
both cell membrane CD8 and, after cell permeabilization carried out
by Cytoperm-Cytoﬁx (BD Pharmingen), intracellular IFN-γ. The
supernatants recovered before brefeldin A treatment were assayed
for the presence of IFN-γ by commercial ELISA (BD Pharmingen).
FACS analysis of iDCs
For the detection of iDC cell surface markers, cells were FACS
analyzed after 1 h incubation at 4 °C with 1:100 dilutions of the
following mAbs: FITC-conjugated anti-CD1a from Dako (Glostrup,
Denmark), PE-conjugated anti-CD14 from BD Pharmingen, FITC-
conjugated anti-HLA-ABC, clone W6/32 from Sigma-Aldrich.
Mice immunization and detection of IFN-γ producing CD8+ lymphocytes
All studies with animals here described have been approved by the
Ethical Committee of the Istituto Superiore di Sanità. C57 Black/6
mice were purchased from Charles River Laboratories (Como, Italy)
and were inoculated subcutaneously three times at 2-week intervals
with 10 μg HIV-1 CAp24 equivalents of (VSV-G) HIV-1-based VLPs or
with 10 μg of rE7 protein prepared as described (Di Bonito et al., 2006)
and emulsiﬁed in incomplete Freund's adjuvant. Two weeks after the
last inoculation, mice were sacriﬁced and splenocytes put in culture in
RPMI 20% FCS in the presence of 5 μg/ml of 8- or 9-mer E7 peptides
already identiﬁed to efﬁciently bind theH-2Kb complex of C57 Black/6
mice (Bauer et al., 1995), i.e., DLYCYEQL (aa 21–28), and RAHYNIVTF
(aa 49–57). TheH-2 Kb bindingHPV E6-speciﬁc KLPQLCTEL (aa 18–26)
and YDFAFRDL (aa 50–57) (Bauer et al., 1995) were used as control
peptides. After 4 days of incubation, IFN -γ ELISpot assay was
performed using commercially available reagents (Mabtech AB,
Hamburg, Germany). Spot-forming cells were analyzed and counted
16 h later using an ELISpot reader (A.EL.VIS. ELISpot reader and
Analysis software GmbH, Hannover, Germany).
ELISA
Sera from inoculated mice were pooled, and two-fold serial
dilutions starting from 1:100 were assayed for the presence of anti-
Gag, Nef, or E7 Abs. The end-point dilution corresponded to a b0.1 OD
absorbance at 450 nm. Each serum was assayed in triplicate, and the
mean of the absorbance valuewas taken as ﬁnal readout. Recombinant
E7 and Nef proteins produced as described (Di Bonito et al., 2006;
Federico et al., 2001), andHIV-1Gag, obtained fromNIHAIDS Research
andReference Research Program,were used for the assay. The proteins
were adsorbed overnight at 4 °C in carbonate buffer (pH 9.4) into
Maxisorp microtiter plates (NUNC, Rochester, NY) at the concentra-
tions of 0.25 μg/well for rE7 and rNef, or 0.1 μg/well for rGag. After a
blocking step of 2 h at 37 °C in PBS containing 3% non-fat dry milk
(NFDM), plates were incubated at 37 °C for 1 h with 100 μl of serially
diluted mouse sera in 1% NFDM-PBS. Speciﬁc antigen–antibody
complexes were detected by a peroxidase-conjugated goat anti-
mouse IgG (GE Healthcare Ltd, UK) using tetramethyl benzidine as
substrate. After 30 min at room temperature, the enzymatic reaction
was stopped by adding 50 μl of 1M sulphuric acid/well.Washing steps
were done with 200 μl/well of PBS containing 0.05 % Tween-20 in an
automatic washer.
CTL assay
Splenocytes from inoculatedmicewere cultured for 4 days in RPMI
20% in the presence of 5 μg/ml of the above described E7 peptides.
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immunomagnetic selection (Miltenyi Biotec., Auburn, CA) and
maintained overnight in RMPI 20% in the presence of 10 U/ml of
rIL-2. After 16 h, EL-4 cells previously treated overnight with E7
peptides were co-cultured with CD8+ mouse splenocytes at different
cell ratios (i.e., from 1:40 to 1:5) in 200 μl of RPMI 20% in U-bottom
96-well plates. After additional 6 h, the co-cultures were labeled with
1:100 diluted FITC-conjugated anti-CD8 mAb (BD Pharmingen), and
EL-4 cell mortality was scored by FACS soon after addition of
propidium iodide at the ﬁnal concentration of 10 μg/ml.
Tumor protection assay
C57 Black/6 mice (nine per group) were inoculated following the
above reported schedule. Twoweeks after the last VLP inoculum,mice
were challenged with 5×104 TC-1 tumor cells/mouse by subcutane-
ous injection. Tumor growth was monitored by visual inspection,
palpation, andmeasure of the tumor nodule diameter once a week for
at least 3 months.
Acknowledgments
This work was supported by grants from the AIDS project of the
Ministry of Health, Rome, Italy. Recombinant HIV-1 Gag protein was
obtained from NIH AIDS Research and Reference Reagent Program.
We are indebted to Rosella Franconi (ENEA, Rome, Italy) for providing
the plasmid carrying the E7GGG open reading frame. We thank Maria
Ferrantini, Department of Cell Biology and Neurosciences, Istituto
Superiore di Sanità, Rome, Italy, for helpful discussions and critically
reading the manuscript and to Julia Neudorfer and Simone Allgayer
for excellent technical assistance. We are indebted to Federica M.
Regini for the excellent editorial assistance.
References
Anderson, R.J., Schneider, J., 2007. Plasmid DNA and viral vector-based vaccines for the
treatment of cancer. Vaccine 25 (Suppl. 2), B24–B34.
Bauer, S., Heeg, K., Wagner, H., Lipford, G.B., 1995. Identiﬁcation of H-2Kb binding and
immunogenic peptides from human papilloma virus tumour antigens E6 and E7.
Scand. J. Immunol. 42, 317–323.
Bellone, S., Pecorelli, S., Cannon, M.J., Santin, A.D., 2007. Advances in dendritic cell-
based therapeutic vaccines for cervical cancer. Expert Rev. Anticancer Ther. 7,
1473–1486.
Bottley, G.,Watherston, O.G., Hiew, Y.L., Norrild, B., Cook, G.P., Blair, G.E., 2008. High-risk
human papillomavirus E7 expression reduces cell-surface MHC class I molecules
and increases susceptibility to natural killer cells. Oncogene 27, 1794–1799.
Bourgault I, V., Moyal, B.M., Ziol, M., Chaboissier, A., Barget, N., Berville, S., Paniel, B.,
Jullian, E., Clerici, T., Maillere, B., Guillet, J.G., 2004. Spontaneous regression of grade
3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-
speciﬁc CD4(+) and CD8(+) T-cell responses. Cancer Res. 64, 8761–8766.
Brinkman, J.A., Hughes, S.H., Stone, P., Caffrey, A.S., Muderspach, L.I., Roman, L.D.,
Weber, J.S., Kast, W.N., 2007. Therapeutic vaccination for HPV induced cervical
cancer. Dis. Markers 23, 337–352.
Bukovsky, A.A., Dorfman, T., Weimann, A., Gottlinger, H.G., 1997. Nef association with
human immunodeﬁciency virus type 1 virions and cleavage by the viral protease.
J. Virol. 71, 1013–1018.
Buonaguro, L., Tornesello, M.L., Tagliamonte, M., Gallo, R.C., Wang, L.X., Kamin-Lewis, R.,
Abdelwahab, S., Lewis, G.K., Buonaguro, F.M., 2006. Baculovirus-derived human
immunodeﬁciency virus type 1 virus-like particles activate dendritic cells and
induce ex vivo T-cell responses. J. Virol. 80, 9134–9143.
Buseyne, F., Le, G.S., Boccaccio, C., Abastado, J.P., Lifson, J.D., Arthur, L.O., Riviere, Y.,
Heard, J.M., Schwartz, O., 2001. MHC-I-restricted presentation of HIV-1 virion
antigens without viral replication. Nat. Med. 7, 344–349.
Cosma, A., Nagaraj, R., Buhler, S., Hinkula, J., Busch, D.H., Sutter, G., Goebel, F.D., Erﬂe, V.,
2003. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-speciﬁc T-helper cell
responses in chronically HIV-1 infected individuals. Vaccine 22, 21–29.
Daftarian, P., Mansour, M., Benoit, A.C., Pohajdak, B., Hoskin, D.W., Brown, R.G., Kast,
W.M., 2006. Eradication of established HPV 16 expressing tumors by a single
administration of a vaccine composed of a liposome-encapsulated CTL-T helper
fusion peptide in a water-in-oil emulsion. Vaccine 24, 5235–5244.
D'Aloja, P., Santarcangelo, A.C., Arold, S., Baur, A., Federico, M., 2001. Genetic and
functional analysis of the human immunodeﬁciency virus (HIV) type 1-inhibiting
F12-HIVnef allele. J. Gen. Virol. 82, 2735–2745.
Di Bonito, P., Grasso, F., Mochi, S., Accardi, L., Dona, M.G., Branca, M., Costa, S., Mariani, L.,
Agarossi, A., Ciotti, M., Syrjanen, K., Giorgi, C., 2006. Serum antibody response tohuman papillomavirus (HPV) infections detected by a novel ELISA technique based
on denatured recombinant HPV16 L1, L2, E4, E6 and E7 proteins. Infect. Agent.
Cancer 1, 6.
Federico, M., Percario, Z., Olivetta, E., Fiorucci, G., Muratori, C., Micheli, A., Romeo, G.,
Affabris, E., 2001. HIV-1 Nef activates STAT1 in human monocytes/macrophages
through the release of soluble factors. Blood 98, 2752–2761.
Fehrmann, F., Laimins, L.A., 2003. Human papillomaviruses: targeting differentiating
epithelial cells for malignant transformation. Oncogene 22, 5201–5207.
Fostel, L.V., Dluzniewska, J., Shimizu, Y., Burbach, B.J., Peterson, E.J., 2006. ADAP is
dispensable for NK cell development and function. Int. Immunol. 18,
1305–1314.
Geretti, A.M., Dings, M.E., van Els, C.A., van Baalen, C.A., Wijnholds, F.J., Borleffs, J.C.,
Osterhaus, A.D., 1996. Human immunodeﬁciency virus type 1 (HIV-1)- and
Epstein-Barr virus-speciﬁc cytotoxic T lymphocyte precursors exhibit different
kinetics in HIV-1-infected persons. J. Infect. Dis. 174, 34–45.
Gorer, P.A., 1950. Studies in antibody response of mice to tumour inoculation. Br. J.
Cancer 4, 372–379.
Green, L.A., Liu, Y., He, J.J., 2009. Inhibition of HIV-1 infection and replication
by enhancing viral incorporation of innate anti-HIV-1 protein A3G: a non-
pathogenic Nef mutant-based anti-HIV strategy. J. Biol. Chem. 284,
13363–13372.
Grgacic, E.V., Anderson, D.A., 2006. Virus-like particles: passport to immune
recognition. Methods 40, 60–65.
He, Y., Munn, D., Falo Jr, L.D., 2007. Recombinant lentivector as a genetic immunization
vehicle for antitumor immunity. Expert. Rev. Vaccines. 6, 913–924.
Hung, C.F., Monie, A., Alvarez, R.D., Wu, T.C., 2007. DNA vaccines for cervical cancer:
from bench to bedside. Exp. Mol. Med. 39, 679–689.
Kattenbeck, B., von, P.A., Rohrhofer, A., Wolf, H., Modrow, S., 1997. Inhibition of
human immunodeﬁciency virus type 1 particle formation by alterations of
deﬁned amino acids within the C terminus of the capsid protein. J. Gen. Virol. 78,
2489–2496.
Klasse, P.J., Sattentau, Q.J., 2002. Occupancy and mechanism in antibody-mediated
neutralization of animal viruses. J. Gen. Virol. 83, 2091–2108.
Kutscher, S., Dembek, C.J., Allgayer, S., Heltai, S., Stadlbauer, B., Biswas, P., Nozza, S.,
Tambussi, G., Bogner, J.R., Stellbrink, H.J., Goebel, F.D., Lusso, P., Tinelli, M., Poli, G.,
Erﬂe, V., Pohla, H., Malnati, M., Cosma, A., 2008. The intracellular detection of MIP-
1beta enhances the capacity to detect IFN-gamma mediated HIV-1-speciﬁc CD8 T-
cell responses in a ﬂow cytometric setting providing a sensitive alternative to the
ELISPOT. AIDS Res. Ther. 5, 22.
Lin, K.Y., Guarnieri, F.G., Staveley-O'Carroll, K.F., Levitsky, H.I., August, J.T., Pardoll, D.M.,
Wu, T.C., 1996. Treatment of established tumors with a novel vaccine that enhances
major histocompatibility class II presentation of tumor antigen. Cancer Res. 56,
21–26.
Liniger, M., Zuniga, A., Naim, H.Y., 2007. Use of viral vectors for the development of
vaccines. Expert Rev. Vaccines 6, 255–266.
Liu, M.A., Ulmer, J.B., 2005. Human clinical trials of plasmid DNA vaccines. Adv. Genet.
55, 25–40.
Luo, L., Li, Y., Ha, S.D., Kang, C.Y., 2007. Hydrophilicity dependent budding and secretion
of chimeric HIV Gag-V3 virus-like particles. Virus Genes 35, 187–193.
Marsac, D., Loirat, D., Petit, C., Schwartz, O., Michel, M.L., 2002. Enhanced presentation
of major histocompatibility complex class I-restricted human immunodeﬁciency
virus type 1 (HIV-1) Gag-speciﬁc epitopes after DNA immunization with vectors
coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 Gag particles.
J. Virol. 76, 7544–7553.
Moris, A., Nobile, C., Buseyne, F., Porrot, F., Abastado, J.P., Schwartz, O., 2004. DC-SIGN
promotes exogenous MHC-I-restricted HIV-1 antigen presentation. Blood 103,
2648–2654.
Muller, B., Daecke, J., Fackler, O.T., Dittmar, M.T., Zentgraf, H., Krausslich, H.G., 2004.
Construction and characterization of a ﬂuorescently labeled infectious human
immunodeﬁciency virus type 1 derivative. J. Virol. 78, 10803–10813.
Munger, K., Baldwin, A., Edwards, K.M., Hayakawa, H., Nguyen, C.L., Owens, M., Grace,
M., Huh, K., 2004. Mechanisms of human papillomavirus-induced oncogenesis.
J. Virol. 78, 11451–11460.
Munz, C., Bickham, K.L., Subklewe, M., Tsang, M.L., Chahroudi, A., Kurilla, M.G., Zhang,
D., O'Donnell, M., Steinman, R.M., 2000. Human CD4(+) T lymphocytes
consistently respond to the latent Epstein–Barr virus nuclear antigen EBNA1.
J. Exp. Med. 191, 1649–1660.
Muratori, C., D'Aloja, P., Superti, F., Tinari, A., Sol-Foulon, N., Sparacio, S., Bosch, V.,
Schwartz, O., Federico, M., 2006. Generation and characterization of a stable cell
population releasing ﬂuorescent HIV-1-based virus like particles in an inducible
way. BMC Biotechnol. 6, 52.
Paliard, X., Liu, Y., Wagner, R., Wolf, H., Baenziger, J., Walker, C.M., 2000. Priming of
strong, broad, and long-lived HIV type 1 p55gag-speciﬁc CD8+ cytotoxic T cells
after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res.
Hum. Retroviruses 16, 273–282.
Pandori, M.W., Fitch, N.J., Craig, H.M., Richman, D.D., Spina, C.A., Guatelli, J.C., 1996.
Producer-cell modiﬁcation of human immunodeﬁciency virus type 1: Nef is a virion
protein. J. Virol. 70, 4283–4290.
Peretti, S., Schiavoni, I., Pugliese, K., Federico, M., 2005. Cell death induced by the herpes
simplex virus-1 thymidine kinase delivered by human immunodeﬁciency virus-1-
based virus-like particles. Mol. Ther. 12, 1185–1196.
Peretti, S., Schiavoni, I., Pugliese, K., Federico, M., 2006. Selective elimination of HIV-1-
infected cells by Env-directed, HIV-1-based virus-like particles. Virology 345,
115–126.
Reading, S.A., Dimmock, N.J., 2007. Neutralization of animal virus infectivity by
antibody. Arch. Virol. 152, 1047–1059.
55P. Di Bonito et al. / Virology 395 (2009) 45–55Sallusto, F., Lanzavecchia, A., 1994. Efﬁcient presentation of soluble antigen by cultured
human dendritic cells is maintained by granulocyte/macrophage colony-stimulat-
ing factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.
J. Exp. Med. 179, 1109–1118.
Schafer, K., Muller, M., Faath, S., Henn, A., Osen, W., Zentgraf, H., Benner, A., Gissmann,
L., Jochmus, I., 1999. Immune response to human papillomavirus 16 L1E7 chimeric
virus-like particles: induction of cytotoxic T cells and speciﬁc tumor protection. Int.
J. Cancer 81, 881–888.
Schwartz, O., Marechal, V., Le, G.S., Lemonnier, F., Heard, J.M., 1996. Endocytosis of
major histocompatibility complex class I molecules is induced by the HIV-1 Nef
protein. Nat. Med. 2, 338–342.
Selvey, L.A., Dunn, L.A., Tindle, R.W., Park, D.S., Frazer, I.H., 1994. Human papillomavirus
(HPV) type 18 E7 protein is a short-lived steroid-inducible phosphoprotein in HPV-
transformed cell lines. J. Gen. Virol. 75, 1647–1653.
Smahel, M., Sima, P., Ludvikova, V., Vonka, V., 2001. Modiﬁed HPV16 E7 genes as DNA
vaccine against E7-containing oncogenic cells. Virology 281, 231–238.
Sparacio, S., Pfeiffer, T., Schaal, H., Bosch, V., 2001. Generation of a ﬂexible cell line with
regulatable, high-level expression of HIV Gag/Pol particles capable of packaging
HIV-derived vectors. Mol. Ther. 3, 602–612.Wagner, R., Deml, L., Fliessbach, H., Wanner, G., Wolf, H., 1994. Assembly and
extracellular release of chimeric HIV-1 Pr55gag retrovirus-like particles. Virology
200, 162–175.
Wang, Z., La, R.C., Lacey, S.F., Maas, R., Mekhoubad, S., Britt, W.J., Diamond, D.J., 2006.
Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine
strategy for CMV infection. J. Clin. Virol. 35, 324–331.
Wonderlich, E.R., Williams, M., Collins, K.L., 2008. The tyrosine binding pocket in
the adaptor protein 1 (AP-1) mu1 subunit is necessary for Nef to recruit AP-1 to
the major histocompatibility complex class I cytoplasmic tail. J. Biol. Chem. 283,
3011–3022.
Yang, T.C., Millar, J.B., Grinshtein, N., Bassett, J., Finn, J., Bramson, J.L., 2007. T-cell
immunity generated by recombinant adenovirus vaccines. Expert. Rev. Vaccines 6,
347–356.
Young, K.R., Ross, T.M., 2006. Elicitation of immunity to HIV type 1 Gag is determined by
Gag structure. AIDS Res. Hum. Retroviruses 22, 99–108.
zum Buschenfelde, C.M., Metzger, J., Hermann, C., Nicklisch, N., Peschel, C., Bernhard, H.,
2001. The generation of both T killer and Th cell clones speciﬁc for the tumor-
associated antigen HER2 using retrovirally transduced dendritic cells. J. Immunol.
167, 1712–1719.
